Research at Oslo University Hospital

Wednesday the 22nd of January oncologist and pathologist from all the University Hospitals in Norway gather at the Norwegian Radium Hospital to discuss implementation of personalized medicine in cancer treatment.

The meeting is organized by the Division of Cancer Medicine at OUS to highlight the needs and challenges related to the advanced molecular diagnostics needed for implementation of personalized medicine in both clinic practice and clinical trials.

National cancer screening programs are widely implemented to reduce cancer incidence and mortality in high-income countries, but there is insufficient knowledge of the utility and potential for harmful consequences of this practice. Several of the programs are introduced without the necessary testing of the methods in advance.
This is the topic of professor Mette Kalager and professor Michael Bretthauer's recent article in the prestigious journal Science.

Tuula Nyman is awarded 57 million kroner for her project “National network for advanced proteomic-infrastructrure”, NAPI in short from the Norwegian Research Council.

Nyman is a researcher at the Department for immunology at the Institute of Clinical Medicine at UiO and Oslo University Hospital, and head of the Proteomics Core Facility.

Oslo University Hospital hereby announce research awards in the following two catagories for 2020:

• Excellent Researcher Award (one prize, 300.000 NOK)
• Early Career Award (two prizes of 150.000 NOK each)

Closing date for nominations: March 2nd 2020.

Theodossis Theodossiou, senior researcher and leader of the Protonics project group at the Department of Radiation Biology, has recently been interviewed for the Smithsonian - the official journal published by the Smithsonian Institution in Washington, D.C.
His views on how natural light may be used in future cancer treatment are presented in a feature article entitled "How Studying Bioluminescent Creatures Is Transforming Medical Science".

Dr. Pierre Chymkowitch from the Department of Microbiology at Oslo University Hospital has recently been granted 8.531 million NOK through the FRIPRO program from The Norwegian Research Council.

The “Researcher Project” receiving support is entitled “Regulation of mitotic transcription by centromeres”. 

Ultimovacs ASA , a pharmaceutical company developing novel immunotherapies against cancer, announces that the universal cancer vaccine UV1 will be investigated in a randomized, multi-center phase II trial in mesothelioma.
Dr. Åslaug Helland, head of the Translational studies on solid tumours research group at the Department of Cancer Genetic, is principal investigator of the study.

Theodossis A. Theodossiou – senior researcher and project group leader at Institute for Cancer Research - was awarded the prize researcher-of-the-year 2019 from the leadership at ICR for his oustanding scientific contribution in 2019. The award of 100 000 NOK is financed by Radiumhospitalets legater and is a personal scholarship for stimulating further excellence in research. 

Professor Johanna Olweus - head of the Experimental Immunotherapy Group at the Department of Cancer Immunology - was awarded the Consolidator Grant from the European Research Council (ERC) for her project on immunotherapy “OUTSOURCE: Outsourcing cancer immunity to healthy donors”.